Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing differentiated biologics for the treatment of inflammatory and immunological (I&I) diseases with high unmet medical needs. Founded in 2022 and headquartered in Waltham, Massachusetts, the company's mission is to reshape the standard of care for patients by overcoming the limitations of existing therapies through advanced antibody engineering, optimizing drug half-life and dosing regimens.

Apogee Therapeutics focuses on developing novel antibody therapeutics for major I&I markets, including atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD). Its lead program, Zumilokibart (APG777), is a subcutaneous, extended half-life monoclonal antibody targeting IL-13, primarily being developed for atopic dermatitis, with ongoing and planned trials for asthma and EoE. The company's pipeline also includes APG279, designed for dual inhibition of IL-13 and OX40L, and APG808, which targets IL-4Rα for COPD, among other early-stage programs.

Led by CEO Michael Henderson, Apogee Therapeutics went public on July 13, 2023, listing on the Nasdaq Global Market under the ticker symbol APGE. The company recently announced positive Phase 2 Part A 52-week data for Zumilokibart (APG777) in atopic dermatitis in March 2026, demonstrating maintenance and deepening of responses. In the same month, Apogee successfully completed a public offering, raising approximately $403 million in gross proceeds to further advance its clinical programs.